Phenotype
|
Conditions
|
Figures
|
branchiostegal ray 1 bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
ceratobranchial 5 bone bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 2. ,
Fig. 4
from Gebuijs et al., 2019
|
ceratobranchial 5 tooth bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
ceratohyal bone decreased length, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
chondrocranium bilateral symmetry, abnormal
|
standard conditions
|
Fig. 2
from Albertson et al., 2007
|
cleithrum bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
embryonic viscerocranium morphogenesis process quality, normal
|
control
|
Fig. 9
from Lovely et al., 2016
|
embryonic viscerocranium morphogenesis process quality, normal
|
chemical treatment: dorsomorphin
|
Fig. 9
from Lovely et al., 2016
|
entopterygoid bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
ethmoid cartilage decreased length, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
head decreased size, abnormal
|
standard conditions
|
Fig. 2. ,
Fig. 3
from Gebuijs et al., 2019
|
head anterior region decreased width, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
Meckel's cartilage decreased length, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
Meckel's cartilage-palatoquadrate cartilage joint decreased width, abnormal
|
standard conditions
|
Fig. 3
from Gebuijs et al., 2019
|
notochord bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
opercle bilateral symmetry, abnormal
|
standard conditions
|
Fig. 3
from Albertson et al., 2007
|
opercle malformed, abnormal
|
standard conditions
|
Fig. 3
from Albertson et al., 2007
|
opercle bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
otic placode decreased amount, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic placode malformed, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic placode mislocalised medially, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic placode formation process quality, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic placode formation process quality, abnormal
|
chemical treatment: SB 431542
|
Fig. 5
from Kwon et al., 2009
|
otic vesicle decreased amount, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic vesicle increased size, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic vesicle malformed, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otic vesicle mislocalised medially, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
otolith bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Gebuijs et al., 2019
|
parasphenoid bone mineralization decreased occurrence, abnormal
|
standard conditions
|
Fig. 2. ,
Fig. 4
from Gebuijs et al., 2019
|
paraxial mesoderm mislocalised medially, abnormal
|
chemical treatment: SB 431542
|
Fig. 4
from Kwon et al., 2009
|
paraxial mesodermal cell fate specification process quality, abnormal
|
chemical treatment: SB 431542
|
Fig. 5
from Kwon et al., 2009
|
regulation of bone remodeling occurrence, abnormal
|
standard conditions
|
Fig. 5
from Albertson et al., 2007
|
ventral mandibular arch bilateral symmetry, abnormal
|
standard conditions
|
Fig. 2
from Albertson et al., 2007
|
ventral mandibular arch malformed, abnormal
|
standard conditions
|
Fig. 2 ,
Fig. 5
from Albertson et al., 2007
|